Results for tag: "Imetelstat"

Imetelstat is a telomerase inhibitor drug developed by Geron Corporation for the treatment of myelodysplastic syndromes (MDS) and myelofibrosis (MF). It is a small molecule that works by blocking the activity of telomerase, an enzyme that helps cancer cells to survive and grow. Imetelstat is the first telomerase inhibitor to be approved by the US Food and Drug Administration (FDA) for the treatment of MDS and MF. The Imetelstat market is a rapidly growing segment of the leukemia drugs market. It is expected to benefit from the increasing prevalence of MDS and MF, as well as the growing demand for novel treatments. Imetelstat is also being studied for the treatment of other types of cancer, such as ovarian cancer and non-small cell lung cancer. Some of the key players in the Imetelstat market include Geron Corporation, Celgene Corporation, Novartis AG, and AstraZeneca plc. Show Less Read more